Immuneering Statistics
Want to see IMRX full AI Analyst Report?
Immuneering (IMRX) Stock Statistics & Valuation Metrics
Total Valuation
Immuneering has a market cap or net worth of $240.27M. The enterprise value is $123.13M.
- Market Cap
- $240.27M
- Enterprise Value
- $123.13M
Share Statistics
Immuneering has 64,763,150 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 64,763,150
- Owned by Insiders
- 9.37%
- Owned by Institutions
- 43.87%
Financial Efficiency
Immuneering’s return on equity (ROE) is -0.26 and return on invested capital (ROIC) is -26.71%.
- Return on Equity (ROE)
- -0.26
- Return on Assets (ROA)
- -0.24
- Return on Invested Capital (ROIC)
- -26.71%
- Return on Capital Employed (ROCE)
- -0.27
- Revenue Per Employee
- 0
- Profits Per Employee
- -861.92K
- Employee Count
- 65
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Immuneering is -3.46. Immuneering’s PEG ratio is -0.06.
- PE Ratio
- -3.46
- PS Ratio
- 0.00
- PB Ratio
- 1.37
- Price to FCF
- -3.74
- Price to Operating Cash Flow
- -3.75
- PEG Ratio
- -0.06
Income Statement
In the last 12 months, Immuneering had revenue of 0 and earned -56.02M in profits. Earnings per share was -1.27.
- Revenue
- 0
- Gross Profit
- -698.89K
- Operating Income
- -59.38M
- Pretax Income
- -56.02M
- Net Income
- -56.02M
- EBITDA
- -55.67M
- Earnings Per Share (EPS)
- -1.27
Cash Flow
In the last 12 months, operating cash flow was -61.56M and capital expenditures -246,365, giving a free cash flow of -61.81M billion.
- Operating Cash Flow
- -61.56M
- Free Cash Flow
- -61.81M
- Free Cash Flow per Share
- -0.96
Dividends & Yields
Immuneering pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -27.11%
- Earnings Yield
- -29.19%
Stock Price Statistics
- Beta
- 1.64
- 52-Week Price Change
- -42.48%
- 50-Day Moving Average
- 4.00
- 200-Day Moving Average
- 4.75
- Relative Strength Index (RSI)
- 47.40
- Average Volume (3m)
- 709.75K
Important Dates
Immuneering upcoming earnings date is Mar 11, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Oct 29, 2026
- Next Earnings Date
- Mar 11, 2027
- Ex-Dividend Date
- ―
Financial Position
Immuneering as a current ratio of 17.50, with Debt / Equity ratio of 1.75%
- Current Ratio
- 17.50
- Quick Ratio
- 17.50
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 2.24
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Immuneering has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Immuneering EV to EBITDA ratio is -2.40, with an EV/FCF ratio of -2.80.
- EV to Sales
- 0.00
- EV to EBITDA
- -2.40
- EV to Free Cash Flow
- -2.80
- EV to Operating Cash Flow
- -2.81
Balance Sheet
Immuneering has $145.41M in cash and marketable securities with $3.53M in debt, giving a net cash position of $141.87M billion.
- Cash & Marketable Securities
- $145.41M
- Total Debt
- $3.53M
- Net Cash
- $141.87M
- Net Cash Per Share
- $2.19
- Tangible Book Value Per Share
- $2.50
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Immuneering is $12.50, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- $12.50
- Price Target Upside
- 236.93% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 2
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- 42.34%
Scores
- Smart Score
- 8
- AI Score
- 47

